PhaseV Applies Machine Learning for Successful Clinical Trials

A clinical trial can cost hundreds of millions of dollars, and one of the major contributors to costs is recruiting and keeping human subjects. According to Dr. Raviv Pryluk, PhD, CEO and co-founder at PhaseV, machine learning can cut the number of subjects by 30 to 50 percent. In this video, he describes other ways that AI can make drug development more efficient. Learn more about PhaseV: https://phasevtrials.com/ Health IT Community: https://www.healthcareittoday.com/